BACKGROUND: @entity79 in @entity177 has a wide spectrum that includes both high and low turnover conditions. Specific preventive and therapeutic measures require knowledge of the nature of bone involvement. Bone biopsy with static and dynamic histomorphometry is the gold standard for characterization of @entity8 . However, non-invasive biochemical tests, especially serum intact @entity461 ( @entity461 ), have a good correlation with histomorphometry. We studied the clinical and biochemical profile of @entity79 in a sample of north Indian @entity1 with @entity177 . METHODS: Twenty-nine @entity1 of @entity177 were evaluated clinically, radiologically ( @entity2681 on hand X-rays) and biochemically (serum @entity460 , @entity3151 , total alkaline phosphatase, intact @entity461 , osteocalcin, @entity14257 , @entity10692 ). Bone histomorphometry could be done in 4 patients. RESULTS: Serum intact @entity461 within or below the non-uraemic normal range, an index of @entity79 , was seen in 17 (58.6%) patients. Serum osteocalcin, a bone formation marker, was within or below the non-uraemic normal range in 65.5% patients. Serum intact @entity461 and osteocalcin had a significant positive correlation (r = 0.6). @entity1 groups with clinical or radiological evidence of @entity79 had serum intact @entity461 and osteocalcin levels comparable to those lacking such features. Serum intact @entity461 and total alkaline phosphatase were lower in haemodialysed (n = 25) @entity1 than in those who had not received haemodialysis (n = 4). Low (< 10 ng/ml) serum @entity14257 levels were seen in 7 (24%) @entity1 while @entity10692 was low (< 15.9 pg/ml) in 20 (69%) @entity1 . The biochemical parameters accurately reflected the bone histology (n = 4). CONCLUSIONS: Our data show that the majority of north Indian @entity1 with @entity177 have biochemical evidence of @entity79 . Empirical use of @entity460 salts and active @entity560 analogues without documentation of parathyroid status carry the risk of further @entity79 .

Calcitropic hormonal status in north Indian XXXX with end-stage renal disease.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal bone disease'] @entity10692 :: ('MESH:C097949', 'Chemical') :: ['1,25-dihydroxyvitamin D'] @entity2681 :: ('MESH:D014077', 'Disease') :: ['subperiosteal erosions'] @entity177 :: ('MESH:D051437', 'Disease') :: ['chronic renal failure'] @entity79 :: ('MESH:D001847', 'Disease') :: ['suppression of bone turnover', 'low bone turnover', 'bone disease', 'Bone disease'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity14257 :: ('MESH:C104450', 'Chemical') :: ['25-hydroxyvitamin D'] @entity3151 :: ('MESH:D010758', 'Chemical') :: ['phosphorus'] @entity461 :: ('5741', 'Gene') :: ['PTH', 'parathyroid hormone'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']
@entity1 :: (9606,Species) :: ['patients']
